On Wednesday morning, Theranexus shares posted one of the biggest rises on the Paris market in sustained volumes, following the announcement of "promising" results from a study in the juvenile form of Batten disease.

Shortly before 12:00 pm, on At 10:40 am, shares in the Lyon-based biopharmaceutical company climbed by almost 10% in volumes representing more than 17 times their daily average over the last four trading sessions.

Data collected after 18 months in the phase 1/2 trial have demonstrated the potential of its Batten-1, with no significant progression of motor symptoms observed in six patients aged over 17.

For Mathieu Charvériat, Theranexus' CEO, this stabilization of motor symptom progression is a very encouraging signal for patients and their families.

The company says it is now considering various financing options to ensure it has adequate resources to launch a pivotal Phase 3 trial, the design of which has already been validated by the US FDA and the European EMA.

Juvenile Batten disease is a rare and fatal genetic disorder of the nervous system, for which there is currently no treatment.

Copyright (c) 2024 CercleFinance.com. All rights reserved.